Analyzing Horizon Therapeutics (HPTX) & Its Rivals

Horizon Therapeutics (NASDAQ: HPTX) is one of 48 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Horizon Therapeutics to related companies based on the strength of its profitability, institutional ownership, analyst recommendations, dividends, valuation, risk and earnings.

Insider and Institutional Ownership

42.7% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 15.3% of shares of all “Biopharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Horizon Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Horizon Therapeutics 23.13% 21.30% 15.42%
Horizon Therapeutics Competitors -13,486.12% -54.03% -24.46%

Valuation and Earnings

This table compares Horizon Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Horizon Therapeutics N/A N/A -1,533.00
Horizon Therapeutics Competitors $584.27 million $101.79 million 59.01

Horizon Therapeutics’ rivals have higher revenue and earnings than Horizon Therapeutics. Horizon Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent recommendations for Horizon Therapeutics and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Horizon Therapeutics 0 0 0 0 N/A
Horizon Therapeutics Competitors 157 818 1802 61 2.62

As a group, “Biopharmaceuticals” companies have a potential upside of 4.42%. Given Horizon Therapeutics’ rivals higher probable upside, analysts plainly believe Horizon Therapeutics has less favorable growth aspects than its rivals.

Summary

Horizon Therapeutics rivals beat Horizon Therapeutics on 5 of the 8 factors compared.

About Horizon Therapeutics

Horizon Therapeutics, Inc., formerly Hyperion Therapeutics, Inc., is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company’s products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder. The Company’s products are used to lower ammonia in the blood. RAVICTI is used to treat urea cycle disorders (UCD). BUPHENYL is indicated as an adjunctive therapy in the chronic management of patients with UCDs involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). The Company sells BUPHENYL under the brand name AMMONAPS in Europe and the Middle East.

Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply